Centers for Medicare & Medicaid Services opened a national coverage analysis to reconsider its 2012 coverage decision regarding transcatheter aortic valve replacement.
Cleveland Clinic physicians have completed a study that shows leadless pacemakers might be a safer option than traditional transvenous pacemakers.
Philips is set to pick up EPD Solutions, a company that specializes in image-guided procedures for cardiac arrhythmias, for about $292 million upfront, in a transaction set to be completed in July.
The private company said the first patient has been treated with its J-Valve TF System for aortic regurgitation.
The company is now gearing up for a larger more in-depth study that could put it on the path to get a nod from FDA.
Medtronic reported earning $8.14 billion in sales for its most recent quarter driven primarily by recent developments and product offerings from its diabetes and cardiovascular units.
If the Amplatzer Amulet Left Atrial Appendage (LAA) occlusion device gains approval in the U.S., the device could go head-to-head with Boston Scientific’s Watchman.
TAVR pioneer Edwards Lifesciences has released positive 30-day data of its Sapien 3 valve at EuroPCR.
Johnson & Johnson’s Cerenovus has stiff competition in the stent retriever market from both Stryker and Medtronic.
Robert Jarvik, MD, 2018 MDEA Lifetime Achievement Award winner, recalls defining moments of his medical innovation career.
Medtronic has initiated a clinical study to see if its Resolute Onyx DES can treat bifurcation lesions, which account for about 20% of all percutaneous coronary interventions.
Ancora Heart said FDA has approved an expansion of the company’s feasibility study to evaluate the AccuCinch Ventricular Repair System designed for the treatment of heart failure and functional mitral regurgitation (FMR).
The TMVR market continues to thrive, but Neovasc is having problems making a significant impact in the promising space, according to its most recent earnings report.